On March 20, 2012, in a 9-0 decision, the U.S. Supreme Court issued its opinion in Mayo Collaborative Servs. v. Prometheus Labs. Inc., No. 10-1150, ruling that two patents covering medical diagnostics owned by Prometheus and asserted against Mayo were invalid, reversing the earlier ruling by the U.S. Court of Appeals for the Federal Circuit that the patents were valid and infringed.
The Supreme Court invalidated the patents covering a method for monitoring a patient’s blood to determine the best dosage for a drug—a decision that will likely adversely impact the personalized medicine industry—ruling that companies could not patent observations about a natural phenomenon. The case had been closely watched within the medical and biotechnology industries because of its impact on the growing and lucrative field of personalized medicine.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
